During the past decade, Gesellschaft für Klinische Forschung Ludwigshafen mbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Gesellschaft für Klinische Forschung Ludwigshafen mbH" are "Brain Metastases" (1 trials), "Malignant Melanoma" (1 trials) and "Metastatic Melanoma" (1 trials). Many other conditions were trialed in "Gesellschaft für Klinische Forschung Ludwigshafen mbH" in a lesser frequency.

Most popular intervention types in "Gesellschaft für Klinische Forschung Ludwigshafen mbH" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Cobimetinib" (1 trials), "Ipilimumab" (1 trials), "Nivolumab" (1 trials) and "Vemurafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gesellschaft für Klinische Forschung Ludwigshafen mbH" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Gesellschaft für Klinische Forschung Ludwigshafen mbH". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Gesellschaft für Klinische Forschung Ludwigshafen mbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gesellschaft für Klinische Forschung Ludwigshafen mbH, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".